Management of comorbidities in haemophilia

Christine L Kempton; Michael Makris; Pål Andre Holme

doi:10.1111/hae.14013

Management of comorbidities in haemophilia

Haemophilia. 2021 Feb:27 Suppl 3:37-45. doi: 10.1111/hae.14013. Epub 2020 Jun 1.

Authors

Christine L Kempton¹, Michael Makris^{2

3}, Pål Andre Holme^{4

5}

Affiliations

¹ Department of Hematology and Medical Oncology and Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA, USA.
² Department of Infection Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
³ Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, UK.
⁴ Department of Haematology, Oslo University Hospital, Oslo, Norway.
⁵ Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

PMID: 32476243
DOI: 10.1111/hae.14013

Abstract

With the introduction of clotting factor concentrates in the early 1970s, significant improvements in quality of life and life expectancy of persons with haemophilia (PWH) were realized. Unfortunately, as a result of transmission of HIV and hepatitis C virus (HCV) by contaminated concentrates in the 1980s, many of these gains were lost. Now with four decades of PWH unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, respectively, the survival rate is once again increasing. In addition to the usual comorbidities associated with advanced age in the general population, several specific issues occur in patients with bleeding disorders. This manuscript explores the incidence and management of the comorbidities of the ageing PWH with a focus on cardiovascular disease and osteoporosis.

Keywords: ageing; cardiovascular diseases; haemophilia; osteoporosis.

MeSH terms

Cardiovascular Diseases* / epidemiology
Comorbidity
Hemophilia A* / complications
Hemophilia A* / epidemiology
Hepatitis C* / complications
Hepatitis C* / epidemiology
Humans
Quality of Life